XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and contingencies - Neurocrine Collaboration Agreement - (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jan. 08, 2023
USD ($)
item
Program
$ / shares
shares
Feb. 28, 2023
USD ($)
item
Program
$ / shares
shares
Mar. 31, 2019
Mar. 31, 2023
USD ($)
Program
Mar. 31, 2022
USD ($)
Neurocrine Collaboration Agreement | Neurocrine          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of collaboration programs | Program       2  
Upfront payment   $ 136,000      
Purchase of common stock, shares | shares   4,395,588      
Purchase of common stock   $ 7,900      
Termination period     10 years    
Period of advance notice for termination prior to first commercial sale     180 days    
Period of advance notice for termination after first commercial sale     1 year    
Period of advance notice for termination after complete readout of clinical trial     30 days    
Discount related to equity investment   39,000      
Allocation of Transaction Price          
Allocation of fixed consideration   $ 143,900   $ 143,880  
Costs to obtain collaboration agreement       400  
Revenue recognized       69,500  
Deferred revenue       74,400  
Neurocrine Collaboration Agreement | Neurocrine | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of reduction in royalty payments     50.00%    
Neurocrine Collaboration Agreement | Neurocrine | GBA1          
Allocation of Transaction Price          
Allocation of fixed consideration       69,459  
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 1          
Allocation of Transaction Price          
Allocation of fixed consideration       24,807  
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 2          
Allocation of Transaction Price          
Allocation of fixed consideration       24,807  
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 3          
Allocation of Transaction Price          
Allocation of fixed consideration       24,807  
Neurocrine Collaborative Agreement 2019 | Neurocrine          
Allocation of Transaction Price          
Revenue recognized       2,000 $ 700
Neurocrine Collaborative Agreement 2023          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option 50.00%        
Percentage of development costs incurred 50.00%        
Neurocrine Collaborative Agreement 2023 | Neurocrine          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of discovery programs | Program 3        
Percentage of profit or loss under co-co option 50.00%        
Percentage of development costs incurred 50.00%        
Purchase of common stock, shares | shares 4,395,588 4,395,588      
Purchase of common stock $ 39,000 $ 39,000      
Price per share | $ / shares $ 8.88 $ 8.88      
Contract expense       $ 200  
Allocation of Transaction Price          
Number of products | item 4        
Neurocrine Collaborative Agreement 2023 | Neurocrine | Development milestone          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of discovery programs | Program   3      
Neurocrine Collaborative Agreement 2023 | Neurocrine | Development milestone | GBA1          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate maximum milestone payments to be received from collaborative partner   $ 985,000      
Neurocrine Collaborative Agreement 2023 | Neurocrine | Development milestone | Discovery Programs 2023          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate maximum milestone payments to be received from collaborative partner   175,000      
Neurocrine Collaborative Agreement 2023 | Neurocrine | Commercial Milestone | GBA1          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Per Milestone, maximum milestone payments to be received from collaborative partner   $ 950,000      
Allocation of Transaction Price          
Number of products | item   2      
Neurocrine Collaborative Agreement 2023 | Neurocrine | Commercial Milestone | Discovery Programs 2023          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Per Milestone, maximum milestone payments to be received from collaborative partner   $ 275,000      
Allocation of Transaction Price          
Number of products | item   1